New capsule aims to fight rare eye cancer that spreads

NCT ID NCT07136181

Recruiting now Disease control Sponsor: Novelwise Pharmaceutical Corporation Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests an experimental drug called NBM-BMX in people with metastatic uveal melanoma, a rare eye cancer that has spread to other parts of the body. The goal is to find the best dose, check for side effects, and see if the drug can shrink or slow tumors. Participants take the capsule twice daily and visit the clinic regularly for checkups.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: NBM-BMX (a capsule that blocks a protein called HDAC8, which may help slow cancer growth)
What this could lead to: If it works, this could point toward a new treatment option for people with metastatic uveal melanoma, a rare and hard-to-treat eye cancer.
What could go wrong: This is an early-phase trial with only 36 participants, so results may not apply to everyone. The drug may cause side effects or fail to shrink tumors.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for EYE CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Neoplasm Metastasis ocular cancer Recurrence uveal melanoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

EYE CANCER EYE CANCER, INTRAOCULAR MELANOMA METASTATIC UVEAL MELANOMA UVEAL MELANOMA, METASTATIC UVEAL MELANOMA, RECURRENT

Contacts and locations

Locations

Honor Health Resarch Institute
RECRUITING

Scottsdale, Arizona, 85258, United States
SCRI Oncology Partners
RECRUITING

Nashville, Tennessee, 37203, United States
Sarah Cannon Research Institute (SCRI) - Denver HealthONE Location
RECRUITING

Denver, Colorado, 80218, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.